Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease - Munyentwali, Helene; Bouachi, Khedidja; Audard, Vincent; Remy, Philippe; Lang, Philippe; Mojaat, Rachid; Deschênes, Georges; Ronco, Pierre M.; Plaisier, Emmanuelle M.; Dahan, Karine Y. (Kidney international, 2013)
Keywords: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antibodies, Monoclonal, Murine-Derived - adverse effects; Antibodies, Monoclonal, Murine-Derived - therapeutic use; Antigens, CD19; Antigens, CD19 - analysis; Antigens, CD20; Antigens, CD20 - immunology; Biochemistry, Molecular Biology; clinical nephrology; Female; Genomics; glomerulopathy; Humans; Immunosuppressive Agents; Immunosuppressive Agents - therapeutic use; Life Sciences; Male; Middle Aged; Nephrosis, Lipoid; Nephrosis, Lipoid - drug therapy; nephrotic syndrome; Prednisone; Prednisone - therapeutic use; Recurrence; Retrospective Studies; Rituximab; clinical nephrology; glomerulopathy; nephrotic syndrome